Trial · NCT07900789
HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer
NCT07900789, Phase 3, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer. Trials, record NCT07900789. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07900789
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer
- NCT number
- NCT07900789
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 825 participants, estimated
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Conditions
- Systemic Treatment-naïve Pancreatic Cancer
- Interventions
HRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection, HRS -4642 + Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection, Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Event-Free Survival (EFS) based on Independent Review Committee according to RECIST v1.1 | From the beginning of randomization to the time of disease progression，about 14-20 months after first dose | |
| Secondary | The rates of pathological complete response (pCR) | about 4-6 months after first dose | Assessed by the independent pathology center and the investigator |
| Secondary | major pathological response (mPR) | about 4-6 months after first dose | Assessed by the independent pathology center and the investigator |
| Secondary | surgical resection rate | about 4-6 months after first dose | Assessed by the investigator |
| Secondary | R0 resection rate | about 4-6 months after first dose | Assessed by the investigator |
| Secondary | objective response rate (ORR) | From the beginning of randomization to the time of disease progression，about 14-20 months after first dose | Assessed by the Independent Review Committee r and the investigator |
| Secondary | disease-free survival (DFS) | From the beginning of randomization to the time of disease progression，about 14-20 months after first dose | Assessed by the Independent Review Committee and the investigator |
| Secondary | event-free survival (EFS) | From the beginning of randomization to the time of disease progression，about 14-20 months after first dose | Assessed by the investigator |
| Secondary | overall survival (OS) | From the beginning of randomization to the time of death，about 30 months after first dose | Assessed by the investigator |
| Secondary | The incidence and severity of adverse events (AEs) | From the beginning of randomization to the time of treatment ended ，about 30 months after first dose | Assessed by the investigator |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07900789
GET https://conductscience.org/api/trials/v1/NCT07900789/registered